Last updated: 2026-10-16 21:22:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Immix Biopharma, Inc. (IMMX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $7.98, with a market capitalization of $705.50M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.61 to $15.10. This page covers its latest market performance, valuation, price trends and company information.
$705.50M | |
$8.67 | |
$15.10 | |
$0.68 | |
$8.68 | |
1.28M | |
1.65M | |
-- | |
$15.10 | |
$2.61 | |
-- | |
-- |
Immix Biopharma, Inc. (IMMX) is trading at $7.98 in after-hours trading as of 2026-10-16 21:20:00, down 8.12% ($0.71) from the regular-session close of $8.68.
After-hours trading shows how investors are pricing IMMX after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Immix Biopharma, Inc. (IMMX) moved from $9.49 to $7.98, representing a decline of 15.91% ($1.51).
The stock traded between $7.96 and $9.69 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.27 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 43.0%
IMMX is currently trading at $7.98, placing it 43.0% of the way from its 52-week low of $2.61 to its 52-week high of $15.10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 21 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Immix Biopharma, Inc. (IMMX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.